New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 23, 2013
16:16 EDTNBIXNeurocrine Biosciences announces VMAT2 inhibitor granted two more patents
Neurocrine Biosciences announced that two additional patents have been granted related to the Company's proprietary Vesicular Monoamine Transporter 2 inhibitor, or VMAT2. European Patent Number 2,081,929 was granted in January 2013 by the European Patent Office with an expiration date of November 2027. The United States Patent and Trademark Office recently granted a second patent. United States Patent Number 8,357,697 covers the method of treating hyperkinetic movement disorders using NBI-98854 and will expire in November 2027.
News For NBIX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 20, 2015
08:02 EDTNBIXNeurocrine announces oral presentation of NBI-77860 trial data
Neurocrine Biosciences announced that the steering committee of ENDO 2015 has selected the abstract of their recently completed clinical study of NBI-77860 in classic congenital adrenal hyperplasia for an oral presentation on the initial day of the Endocrine Society's 97th Annual Meeting. The ENDO 2015 meeting will be held in San Diego from March 5-8.
07:52 EDTNBIXNeurocrine price target raised to $39 from $32 at Jefferies
Subscribe for More Information
January 16, 2015
14:31 EDTNBIXNeurocrine confirms FDA grants orphan status to NBI-77860
Subscribe for More Information
12:05 EDTNBIXNeurocrine granted orphan status for CAH treatment
Subscribe for More Information
January 14, 2015
10:21 EDTNBIXOptions with decreasing implied volatility
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use